Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/31/2007

FRAZER, Pa., Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

"TREANDA is the lead product in our oncology pipeline and with this second NDA submission for the product in 2007 we have achieved a significant milestone for our business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "The clinical data supporting this submission highlight the potential of TREANDA to make a meaningful difference for patients with indolent NHL who have relapsed during or following treatment with rituximab."

The TREANDA NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents.

About TREANDA

TREANDA is a novel chemotherapeutic agent, a hybrid of a purine analog and an alkylator. Preclinical data demonstrate that TREANDA acts in two distinct ways to kill cancer cells. TREANDA damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death (non-apoptotic) pathway known as mitotic catastrophe (a disruption of no
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Amici Procurement Migrates ... company Amici Procurement has chosen Microsoft Cloud Solution Provider ... to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... medium-sized companies in the bio-tech sector with a unique ... purchasing cycle to help them obtain best value. Its ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... 2007, Wyeth (NYSE: WYE ) will announce financial ... a one-hour conference call with,research analysts at 7:30 a.m. ... may listen to the call live or on a ... by visiting our website,at http://www.wyeth.com and clicking ...
... China Technology,Development Group Corporation (Nasdaq: CTDC; "CTDC" ... strategy of entering the booming solar energy,sector. ... China,s,use of renewable energy in the coming ... the new business strategy will deliver shareholder,value ...
... 7 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... Annual Healthcare Conference in New York will be webcast,and ... http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) A member of Human ... the company on Tuesday, September 11, 2007 at 4:00 ...
Cached Biology Technology:China Technology Announces Entry to the Solar Energy Sector 2China Technology Announces Entry to the Solar Energy Sector 3
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... -- Richard Amasino, former president of the American ... nearly $4.7 million grant from the U.S. Department ... (NIFA) to strengthen K󈝼 education related to sustainable ... Baxter Lauffer, who are both at the University ...
... MedNet Solutions, a global life sciences technology solutions ... pleased to announce the latest release of ... ENLIGHTEN system, which provides a proven, ... and clinical trial management system (CTMS), has effectively ...
... look twice at their ability to exhibit the "Cheerios effect" ... will actually stick together like Cheerios swimming in milk in ... force." This observation has made Virginia Tech engineers speculate about ... work appears in the journal, Soft Matter , a ...
Cached Biology News:Former ASPB president leading sustainable bioenergy education project 2MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2When worms stick together and swim on thin water, what happens and why does it matter? 2
Request Info...
... Kit Contains the following: , Coated Capture Antibody: ... , Wash/Sample Diluent: 300 mL of 2X concentrate ... 10 microg lyophilized peptide , Lyophilized Standard Diluent: ... 50X concentrate , Secondary Antibody-HRP: 30 microL of ...
carnitine deficiency-associated gene expressed in ventricle 1...
... Clone/PAD: ZMD.471. Immunogen: Synthetic peptide ... the mouse junctophilin-1. Specificity: Specific ... Mouse (positive controls: mouse brain and ... and skeletal muscle tissues). Applications: ...
Biology Products: